Altre lingue Mendus AB

Azioni

Mercato chiuso - Nasdaq Stockholm Altri mercati azionari 17:19:42 24/04/2024			Variaz. 5gg	Var. 1 gen.
0,49 ^SEK	-1,31%		-3,92%	-6,31%

16/04	Mendus AB (Publ) annuncia cambiamenti nel Consiglio di Amministrazione	CI
27/03	Mendus AB (publ) annuncia l'approvazione del Comitato Etico per lo studio AMLM22-CADENCE con il prodotto di punta Vididencel nella LAM.	CI

Mendus publishes Annual Report for 2023	17/04
Notice of Annual General Meeting in Mendus AB (publ)	16/04
Mendus AB Announces Board Changes	16/04
Mendus to participate in upcoming industry conferences	08/04
Mendus raises approximately SEK 69.1 million through the warrants of series TO3	02/04
Nomination committee proposes CMC specialist to Elicera's board of directors	28/03
Mendus announces ethics committee approval for the AMLM22-CADENCE trial with lead product vididencel in AML	27/03
Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML	27/03
Mendus to present NK cell program progress at the Innate Killer Summit	19/03
Mendus to present NK cell program progress at the Innate Killer Summit	19/03
Mendus' : major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3	15/03
Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3	15/03
The exercise period for warrants of series TO3 commences today	15/03
The exercise period for warrants of series TO3 commences today	15/03
Mendus provides business update and outlook for vididencel program	12/03
Mendus to participate in upcoming industry conferences	27/02
Mendus to participate in upcoming industry conferences	27/02
Mendus to hold Business Update event on March 12	23/02
Mendus Q4 2023 - Gearing up for CADENCE	14/02
Mendus AB Year-end Report for 2023	14/02

Non ci sono risultati per questa ricerca